Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

TNF alpha antibody (Tumor Necrosis Factor alpha) Primary Antibody

TNF alpha Reactivity: Human BR, ELISA, FACS, IP, WB Host: CHO Cells Monoclonal Etanercept unconjugated
Catalog No. ABIN6730998
$360.00
Plus shipping costs $45.00
100 μL
local_shipping Shipping to: United States
Delivery in 7 to 8 Business Days
  • Target
    TNF alpha
    Antibody Type
    Recombinant Antibody
    Reactivity
    • 418
    • 184
    • 139
    • 49
    • 41
    • 35
    • 29
    • 29
    • 23
    • 13
    • 12
    • 12
    • 8
    • 8
    • 6
    • 5
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Host
    • 292
    • 263
    • 43
    • 32
    • 6
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    CHO Cells
    Clonality
    • 342
    • 293
    • 4
    Monoclonal
    Conjugate
    • 329
    • 91
    • 52
    • 22
    • 20
    • 16
    • 8
    • 6
    • 6
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 2
    • 2
    • 2
    • 2
    • 1
    This TNF alpha antibody is un-conjugated
    Application
    • 316
    • 293
    • 200
    • 172
    • 89
    • 65
    • 62
    • 59
    • 53
    • 50
    • 50
    • 45
    • 35
    • 28
    • 19
    • 16
    • 14
    • 10
    • 10
    • 8
    • 8
    • 7
    • 7
    • 7
    • 6
    • 4
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB)
    Purpose
    The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive.
    Specificity
    "The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive."
    Characteristics
    "This is a dimeric fusion protein derived from Enbrel and designed for research purposes. Etanercept, the active ingredient of Enbrel, is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF." Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55- kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF biological activity.
    TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion element in the construction of a dimeric receptor imparts a longer serum half-life.
    Purification
    The commercial therapeutic mAb was diluted with sterile PBS to a final 1 mg/ml.  (original drug Enbrel 50 was diluted 1:50)
    Sterility
    Sterile
    Clone
    Etanercept
  • Application Notes
    Optimal dilution for a specific application should be determined by user
    Comment

    Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. Etanercept is a dimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human tumour necrosis factor receptor-2 (TNFR2/p75) to the Fc domain of human IgG1. This Fc component contains the hinge, CH2and CH3regions, but not the CH1region of IgG1. Etanercept contains 934amino acids and has an apparent molecular weight of approximately 150 kilodaltons. The specific activity of etanercept is 1.7x 106units/mg.

    Protocol
    Research-relevant quantities are available as licence-free consumable as diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    The dilutant is sterile PBS pH 7.4. No preservatives added
    Preservative
    Without preservative
    Handling Advice
    open only under sterile conditions
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
    Expiry Date
    48 months
  • Target
    TNF alpha
    Alternative Name
    TNF-alpha (TNF alpha Antibody Abstract)
    Synonyms
    DIF, TNF-alpha, TNFA, TNFSF2, RATTNF, Tnfa, tnf, TNF-a, TNFalpha, Tnfsf1a, TNFa, cTNF, Tnf-alpha, tnfa-like, TNF-ALPHA, dif, tnfa, xtnf, tnfsf2, tnf-alpha, Cachectin, tumor necrosis factor, tumor necrosis factor b (TNF superfamily, member 2), tumor necrosis factor alpha, tumor necrosis factor a (TNF superfamily, member 2), TNF, Tnf, tnf, tnfb, tnf-alpha, LOC103694380, tnfa
    Background
    Synonyms: DIF, TNF-alpha, TNFA, TNFSF2, RATTNF, Tnfa, tnf, TNF-a, TNFalpha, Tnfsf1a, TNFa, cTNF, Tnf-alpha, tnfa-like, TNF-ALPHA, dif, tnfa, xtnf, tnfsf2, tnf-alpha, Cachectin
    Molecular Weight
    26 kDa
    Gene ID
    21926
    NCBI Accession
    NM_000594
    UniProt
    P01375
    Pathways
    NF-kappaB Signaling, Apoptosis, Caspase Cascade in Apoptosis, TLR Signaling, Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Inflammasome
You are here:
help Support